Abstract
Abstract
Background:
Identifying people who are at risk of deteriorating and dying is essential to inform goals of care, appropriate treatment decisions, patient autonomy, and effective end-of-life care. Limited literature exists on predicting survival near the end of life for people with a hematological malignancy.
Objective:
To identify the key clinical indicators that signal a person with a hematological malignancy is at high risk of deteriorating and dying.
Design, Setting, Participants:
Eleven clinical indicators identified in a Delphi approach were tested via a retrospective case–control study. Each indicator was assessed for at each in-patient admission between living (n = 236) and deceased (n = 120) people with a hematological malignancy who were admitted to a large tertiary hospital between 1st July 2014 and 31st December 2015.
Results:
Six clinical indicators were independently associated with mortality in the final three months of life: declining performance status (Odds Ratio [OR] 7.153, 95% Confidence Intervals [CI] 3.281–15.597, p = < 0.001); treatment limitations of the hematological malignancy (OR 7.855, 95% CI 3.528–17.489, p = < 0.001); relapse, refractory or persistent disease (OR 3.749, 95% CI 1.749–8.039, p = 0.001); presence of two or more comorbidities (OR 2.991, 95% CI 1.319–6.781, p = 0.009); invasive fungal infections (OR 4.887, 95% CI 1.197–19.949, p = 0.027); and persistent infections (OR 6.072, 95% CI 2.551–14.457, p = < 0.001).
Conclusions:
This study has identified six clinical indicators that signal a person with a hematological malignancy is at high risk of deteriorating and dying and may benefit from an assessment of palliative needs and proactive planning, along-side appropriate treatment.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
